Government-Owned Inventions; Availability for Licensing, 47217-47218 [2011-19817]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 150 / Thursday, August 4, 2011 / Notices
encouraged for use in all types of
royalty payments with NIH.
FOR FURTHER INFORMATION CONTACT:
Companies looking to save time on their
royalty transactions with NIH can easily
pay royalties on Pay.gov by going to
https://www.pay.gov and clicking on
NIH in the agency list. Pay.gov is
maintained by the U.S. Department of
the Treasury. For more information
about the Pay.gov system itself, visit
https://www.pay.gov/paygov/faqs.html.
Dated: July 28, 2011.
Steven M. Ferguson,
Deputy Director, Licensing &
Entrepreneurship, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2011–19821 Filed 8–3–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
sroberts on DSK5SPTVN1PROD with NOTICES
SUMMARY:
CDK4–Transformed Mouse Podocytes
Useful for Studying Glomerular
Diseases
Description of Technology: Podocytes,
cells of the visceral epithelium in the
kidneys, are a key component of the
glomerular filtration barrier. Podocyte
damage and loss contribute to the
initiation of glomerular diseases. Cyclindependent kinase 4 (CDK4), a catalytic
subunit of the cyclin D–CDK4 serine/
VerDate Mar<15>2010
17:29 Aug 03, 2011
Jkt 223001
threonine kinase complex, is a critical
regulator of the cell cycle. Recent
studies showed that cells immortalized
with CDK4 are useful to study
pathophysiology. NIH investigators have
generated mouse podocytes transformed
with CDK4 as a nonviral immortalizing
gene. These transformed podocytes
show podocyte characteristics and
express podocyte markers. Furthermore,
confluent CDK4-podocyte cultures show
higher levels of gene expression for
multiple podocyte differentiation genes
compared with subconfluent or lower
density culture.
Development Stage:
• Early-stage.
• Pre-clinical.
• In vitro data available.
Potential Commercial Applications:
• Model system for study of
glomerular disorders.
• Useful tools to study podocyte
biology.
Competitive Advantage: Better model
system to study podocyte structure and
function.
Inventors: Drs. Toru Sakairi and
Jeffrey B. Kopp (NIDDK).
Publication: Sakairi T, et al. Cell-cell
contact regulates gene expression in
CDK4-transformed mouse podocytes.
Am J Physiol Renal Physiol. 2010
Oct;299(4):F802–809. [PMID: 20668098].
Intellectual Property: HHS Reference
No. E–287–2010/0—Research Tool
(Materials available for licensing: CDK4
podocytes). Patent protection is not
being pursued for this technology.
Related Technology: HHS Reference
No. E–049–2007/0—Model for Study of
Glomerular Disorders: ConditionallyImmortalized Mouse Podocyte Cell Line
with Tet-on-Regulated Gene Expression
(Dr. Jefferey B. Kopp, NIDDK).
Licensing Contact: Suryanarayana
(Sury) Vepa, PhD; 301–435–5020;
vepas@mail.nih.gov.
Conditionally Immortalized Human
Podocyte Cell Lines
Description of Technology: Podocytes,
cells of the visceral epithelium in the
kidneys, are a key component of the
glomerular filtration barrier. Podocyte
damage and loss contribute to the
initiation of glomerular diseases. NIH
investigators recently established longterm urinary cell cultures from two
patients with focal segmental
glomerulosclerosis and two healthy
volunteers, via transformation with the
thermosensitive SV40 large T antigen
(U19tsA58) together with human
telomerase (hTERT). Characterization of
randomly selected clonal cell lines from
each human subject showed mRNA
expression for the podocyte markers
synaptopodin, nestin, and CD2AP in all
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
47217
clones. Podocin mRNA was absent from
all clones. The expression of nephrin,
Wilms tumor 1 (WT1), and podocalyxin
mRNA varied among the clones, which
may be due to transformation and/or
cloning. These novel human urinederived podocyte-like epithelial cell
lines (HUPECs) generated from urine of
patients and healthy volunteers will be
useful to study podocyte cell biology.
Development Stage:
• Early-stage.
• Pre-clinical.
• In vitro data available.
Potential Commercial Applications:
• Model system for study of
glomerular disorders.
• Useful tools to study podocyte
biology.
Competitive Advantage: These
podocyte-like cells are unique and novel
compared to the currently available
podocyte cells because these are
obtained from individuals with
glomerular disease.
Inventors: Drs. Toru Sakairi and
Jeffrey B. Kopp (NIDDK).
Publication: Sakairi T, et al.
Conditionally immortalized human
podocyte cell lines established from
urine. Am J Physiol Renal Physiol. 2010
Mar;298(3):F557–67. [PMID: 19955187]
Intellectual Property: HHS Reference
No. E–252–2010/0—Research Tool.
Patent protection is not being pursued
for this technology.
Related Technologies:
• HHS Reference No. E–049–2007/
0—Model for Study of Glomerular
Disorders: Conditionally-Immortalized
Mouse Podocyte Cell Line with Tet-onRegulated Gene Expression (Dr. Jefferey
B. Kopp, NIDDK).
• HHS Reference No. E–287–2010/
0—CDK4–Transformed Mouse
Podocytes Useful for Studying
Glomerular Diseases (Drs. Toru Sakairi
and Jeffrey B. Kopp, NIDDK)
Licensing Contact: Suryanarayana
(Sury) Vepa, PhD; 301–435–5020;
vepas@mail.nih.gov.
An In-Vitro Cell System Useful For
Identification of RORg Antagonists
Description of Technology: The
retinoid-related orphan receptors alpha,
beta and gamma (RORa, b and g, also
referred to as NR1F1, 2 and 3,
respectively) comprise a distinct
subfamily of nuclear receptors. Study of
ROR-deficient mice has implicated
RORs in the regulation of a number of
biological processes and revealed
potential roles for these proteins in
several pathologies. NIH investigators
have developed an in-vitro system using
CHO cells stably expressing a TET-On
expression vector regulating RORg and a
RORE-Luciferase reporter. This system
E:\FR\FM\04AUN1.SGM
04AUN1
sroberts on DSK5SPTVN1PROD with NOTICES
47218
Federal Register / Vol. 76, No. 150 / Thursday, August 4, 2011 / Notices
allows inducible expression of RORg
upon addition of doxycycline. Upon its
induction RORg binds to the RORE in
the luciferase reporter plasmid and
induces luciferase. This system can be
used to identify RORg antagonists. This
system has been tested successfully in
1536-well plate high throughput
analysis.
Potential Commercial Applications:
Identification of therapeutic compounds
to treat asthma, inflammation, and
various autoimmune diseases such as
osteoarthritis, multiple sclerosis.
Competitive Advantages: Novel and
unique system to screen and identify
chemical and drugs for their RORg
antagonistic activity.
Development Stage:
• Early-stage.
• Pre-clinical.
• In vitro data available.
Inventors: Drs. Yukimasa Takeda and
Anton M. Jetten (NIEHS).
Publications:
1. Jetten AM. Retinoid-related
receptors (RORs): Critical roles in
development, immunity, circadian
rhythm, and cellular metabolism. Nucl
Recept Signal. 2009;7:1–32. [PMID:
19381306].
2. Yang XO, et al. T helper 17 lineage
differentiation is programmed by
orphan receptors ROR alpha and ROR
gamma. Immunity 2008 Jan;28(1):29–39.
[PMID: 18164222].
3. Kurebayashi S, et al. Retinoidrelated orphan receptor gamma
(RORgamma) is essential for lymphoid
organogenesis and controls apoptosis
during thymopoiesis. Proc Natl Acad
Sci USA. 2000 Aug 29;97(18):10132–
10137. [PMID:10963675].
Intellectual Property: HHS Reference
No. 253–2010/0—Research Tool. Patent
protection is not being pursued for this
technology.
Related Technology: HHS Reference
No. E–222–2009/0—RORgamma (RORC)
Deficient Mice Which Are Useful for the
Study of Lymph Node Organogenesis
and Immune Responses (Dr. Anton M.
Jetten, NIEHS).
Licensing Contact: Suryanarayana
(Sury) Vepa, PhD; 301–435–5020;
vepas@mail.nih.gov.
Collaborative Research Opportunity:
The NIEHS, Laboratory of Respiratory
Biology, Cell Biology Group, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize retinoid-related orphan
receptors (RORs) function in chronic
diseases. For collaboration
opportunities, please contact Elizabeth
M. Denholm, PhD at
denholme@niehs.nih.gov.
VerDate Mar<15>2010
17:29 Aug 03, 2011
Jkt 223001
Dated: July 27, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2011–19817 Filed 8–3–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke Amended; Notice
of Meeting
Notice is hereby given of a change in
the meeting of the National Institute of
Neurological Disorders and Stroke
Special Emphasis Panel, August 2, 2011,
9 a.m. to August 2, 2011, 3 p.m.,
National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 which
was published in the Federal Register
on July 20, 2011, 76FFRN43333–43334.
The meeting has been rescheduled for
August 23, 2011. The time and meeting
location remain the same. The meeting
is closed to the public.
Dated: July 29, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–19813 Filed 8–3–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel,
Training Grant Review.
Date: August 24, 2011.
Time: 10:30 a.m. to 4:30 p.m.
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Roy L. White, PhD,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7176, Bethesda, MD 20892–7924, 301–435–
0310, whiterl@nhlbi.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel,
Ancillary Studies Review.
Date: August 26, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Tony L. Creazzo, PhD,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7180, Bethesda, MD 20892–7924, 301–435–
0725, creazzotl@mail.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel,
Research Dissemination and Implementation
Grants.
Date: August 26, 2011.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Keith A. Mintzer, PhD,
Scientific Review Officer, Review Branch/
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7186,
Bethesda, MD 20892–7924, 301–435–0280,
mintzerk@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: July 29, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–19796 Filed 8–3–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
E:\FR\FM\04AUN1.SGM
04AUN1
]]>Agencies
[Federal Register Volume 76, Number 150 (Thursday, August 4, 2011)]
[Notices]
[Pages 47217-47218]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-19817]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
CDK4-Transformed Mouse Podocytes Useful for Studying Glomerular
Diseases
Description of Technology: Podocytes, cells of the visceral
epithelium in the kidneys, are a key component of the glomerular
filtration barrier. Podocyte damage and loss contribute to the
initiation of glomerular diseases. Cyclin-dependent kinase 4 (CDK4), a
catalytic subunit of the cyclin D-CDK4 serine/threonine kinase complex,
is a critical regulator of the cell cycle. Recent studies showed that
cells immortalized with CDK4 are useful to study pathophysiology. NIH
investigators have generated mouse podocytes transformed with CDK4 as a
nonviral immortalizing gene. These transformed podocytes show podocyte
characteristics and express podocyte markers. Furthermore, confluent
CDK4-podocyte cultures show higher levels of gene expression for
multiple podocyte differentiation genes compared with subconfluent or
lower density culture.
Development Stage:
Early-stage.
Pre-clinical.
In vitro data available.
Potential Commercial Applications:
Model system for study of glomerular disorders.
Useful tools to study podocyte biology.
Competitive Advantage: Better model system to study podocyte
structure and function.
Inventors: Drs. Toru Sakairi and Jeffrey B. Kopp (NIDDK).
Publication: Sakairi T, et al. Cell-cell contact regulates gene
expression in CDK4-transformed mouse podocytes. Am J Physiol Renal
Physiol. 2010 Oct;299(4):F802-809. [PMID: 20668098].
Intellectual Property: HHS Reference No. E-287-2010/0--Research
Tool (Materials available for licensing: CDK4 podocytes). Patent
protection is not being pursued for this technology.
Related Technology: HHS Reference No. E-049-2007/0--Model for Study
of Glomerular Disorders: Conditionally-Immortalized Mouse Podocyte Cell
Line with Tet-on-Regulated Gene Expression (Dr. Jefferey B. Kopp,
NIDDK).
Licensing Contact: Suryanarayana (Sury) Vepa, PhD; 301-435-5020;
vepas@mail.nih.gov.
Conditionally Immortalized Human Podocyte Cell Lines
Description of Technology: Podocytes, cells of the visceral
epithelium in the kidneys, are a key component of the glomerular
filtration barrier. Podocyte damage and loss contribute to the
initiation of glomerular diseases. NIH investigators recently
established long-term urinary cell cultures from two patients with
focal segmental glomerulosclerosis and two healthy volunteers, via
transformation with the thermosensitive SV40 large T antigen (U19tsA58)
together with human telomerase (hTERT). Characterization of randomly
selected clonal cell lines from each human subject showed mRNA
expression for the podocyte markers synaptopodin, nestin, and CD2AP in
all clones. Podocin mRNA was absent from all clones. The expression of
nephrin, Wilms tumor 1 (WT1), and podocalyxin mRNA varied among the
clones, which may be due to transformation and/or cloning. These novel
human urine-derived podocyte-like epithelial cell lines (HUPECs)
generated from urine of patients and healthy volunteers will be useful
to study podocyte cell biology.
Development Stage:
Early-stage.
Pre-clinical.
In vitro data available.
Potential Commercial Applications:
Model system for study of glomerular disorders.
Useful tools to study podocyte biology.
Competitive Advantage: These podocyte-like cells are unique and
novel compared to the currently available podocyte cells because these
are obtained from individuals with glomerular disease.
Inventors: Drs. Toru Sakairi and Jeffrey B. Kopp (NIDDK).
Publication: Sakairi T, et al. Conditionally immortalized human
podocyte cell lines established from urine. Am J Physiol Renal Physiol.
2010 Mar;298(3):F557-67. [PMID: 19955187]
Intellectual Property: HHS Reference No. E-252-2010/0--Research
Tool. Patent protection is not being pursued for this technology.
Related Technologies:
HHS Reference No. E-049-2007/0--Model for Study of
Glomerular Disorders: Conditionally-Immortalized Mouse Podocyte Cell
Line with Tet-on-Regulated Gene Expression (Dr. Jefferey B. Kopp,
NIDDK).
HHS Reference No. E-287-2010/0--CDK4-Transformed Mouse
Podocytes Useful for Studying Glomerular Diseases (Drs. Toru Sakairi
and Jeffrey B. Kopp, NIDDK)
Licensing Contact: Suryanarayana (Sury) Vepa, PhD; 301-435-5020;
vepas@mail.nih.gov.
An In-Vitro Cell System Useful For Identification of ROR[gamma]
Antagonists
Description of Technology: The retinoid-related orphan receptors
alpha, beta and gamma (ROR[alpha], [beta] and [gamma], also referred to
as NR1F1, 2 and 3, respectively) comprise a distinct subfamily of
nuclear receptors. Study of ROR-deficient mice has implicated RORs in
the regulation of a number of biological processes and revealed
potential roles for these proteins in several pathologies. NIH
investigators have developed an in-vitro system using CHO cells stably
expressing a TET-On expression vector regulating ROR[gamma] and a RORE-
Luciferase reporter. This system
[[Page 47218]]
allows inducible expression of ROR[gamma] upon addition of doxycycline.
Upon its induction ROR[gamma] binds to the RORE in the luciferase
reporter plasmid and induces luciferase. This system can be used to
identify ROR[gamma] antagonists. This system has been tested
successfully in 1536-well plate high throughput analysis.
Potential Commercial Applications: Identification of therapeutic
compounds to treat asthma, inflammation, and various autoimmune
diseases such as osteoarthritis, multiple sclerosis.
Competitive Advantages: Novel and unique system to screen and
identify chemical and drugs for their ROR[gamma] antagonistic activity.
Development Stage:
Early-stage.
Pre-clinical.
In vitro data available.
Inventors: Drs. Yukimasa Takeda and Anton M. Jetten (NIEHS).
Publications:
1. Jetten AM. Retinoid-related receptors (RORs): Critical roles in
development, immunity, circadian rhythm, and cellular metabolism. Nucl
Recept Signal. 2009;7:1-32. [PMID: 19381306].
2. Yang XO, et al. T helper 17 lineage differentiation is
programmed by orphan receptors ROR alpha and ROR gamma. Immunity 2008
Jan;28(1):29-39. [PMID: 18164222].
3. Kurebayashi S, et al. Retinoid-related orphan receptor gamma
(RORgamma) is essential for lymphoid organogenesis and controls
apoptosis during thymopoiesis. Proc Natl Acad Sci USA. 2000 Aug
29;97(18):10132-10137. [PMID:10963675].
Intellectual Property: HHS Reference No. 253-2010/0--Research Tool.
Patent protection is not being pursued for this technology.
Related Technology: HHS Reference No. E-222-2009/0--RORgamma (RORC)
Deficient Mice Which Are Useful for the Study of Lymph Node
Organogenesis and Immune Responses (Dr. Anton M. Jetten, NIEHS).
Licensing Contact: Suryanarayana (Sury) Vepa, PhD; 301-435-5020;
vepas@mail.nih.gov.
Collaborative Research Opportunity: The NIEHS, Laboratory of
Respiratory Biology, Cell Biology Group, is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize retinoid-
related orphan receptors (RORs) function in chronic diseases. For
collaboration opportunities, please contact Elizabeth M. Denholm, PhD
at denholme@niehs.nih.gov.
Dated: July 27, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2011-19817 Filed 8-3-11; 8:45 am]
BILLING CODE 4140-01-P
